Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
1.295
+0.025 (1.97%)
At close: Mar 13, 2026, 4:00 PM EDT
1.309
+0.014 (1.09%)
After-hours: Mar 13, 2026, 6:53 PM EDT
Neuronetics Revenue
Neuronetics had revenue of $37.30M in the quarter ending September 30, 2025, with 101.28% growth. This brings the company's revenue in the last twelve months to $129.87M, up 78.62% year-over-year. In the year 2024, Neuronetics had annual revenue of $74.89M with 4.96% growth.
Revenue (ttm)
$129.87M
Revenue Growth
+78.62%
P/S Ratio
0.68
Revenue / Employee
$181,387
Employees
716
Market Cap
88.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74.89M | 3.54M | 4.96% |
| Dec 31, 2023 | 71.35M | 6.14M | 9.42% |
| Dec 31, 2022 | 65.21M | 9.89M | 17.89% |
| Dec 31, 2021 | 55.31M | 6.07M | 12.32% |
| Dec 31, 2020 | 49.24M | -13.41M | -21.41% |
| Dec 31, 2019 | 62.66M | 9.88M | 18.72% |
| Dec 31, 2018 | 52.78M | 12.34M | 30.53% |
| Dec 31, 2017 | 40.43M | 6.21M | 18.13% |
| Dec 31, 2016 | 34.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 212.69M |
| Xtant Medical Holdings | 133.08M |
| Pulmonx | 90.50M |
| MaxCyte | 34.42M |
| Baird Medical Investment Holdings | 31.86M |
| Sensus Healthcare | 27.48M |
| QT Imaging Holdings | 18.93M |
| Hyperfine | 10.59M |
STIM News
- 4 weeks ago - Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 months ago - Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November - Benzinga
- 4 months ago - TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression - GlobeNewsWire
- 4 months ago - Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan - GlobeNewsWire
- 4 months ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence - GlobeNewsWire